In xenograft models derived from patients with EGFR or HER2 exon 20 mutant NSCLC and in genetically engineered NSCLC mouse models, poziotinib demonstrated superior activity compared to currently approved EGFR TKIs [16]. Here, EGFR is linked to non-small cell lung carcinoma.